Page 41 - myeong_shin_ebook_2019

2019 Eunoia

Han Seung-yeon

Recently, something shocking happened in the medical
community. It was the Invossa affair. Invossa has been
used for decades as a cell gene therapy treatment for
osteoarthritis. But recently, it turned out that the ingredient
Yingbo is not cartilage1) but experimental growth cells.

This fact is problematic not simply because human-
originated growth cells were misused but because the
infinitely increasing cells used in laboratories as tools for the
manifestation of proteins were injected into a patient's body as if they were cartilage cells. In other words,
they injected cells which had great potential to develop into cancer cells.

The Korean Ministry of Food and Drug Safety (KFDA)
announced on Thursday that it requested Kolon Life
Sciences to stop manufacturing and selling one of the main
ingredients of Invossa, believed to be different from what
was listed in the data which was submitted for approval.
Prior to the KFDA's request, Kolon Life Sciences confirmed
that the two ingredients were different from the submission
data when it was granted permission to be used in Korea
and notified the KFDA. In order to ensure the safety of
its patients, the KFDA plans to strengthen its health
impact investigation by expanding its long-term follow-up
investigations of abnormal cases and patients.

The exact reason for this mistake is not yet known, but
it seems to raise people's awareness of the importance of
attention to approving new drugs.

__________________________________________________
1) cartilage 연골

41MYEONG-SHIN GIRLS' HIGH SCHOOL